File(s) under permanent embargo
Comparing the renal outcomes in patients with atrial fibrillation receiving different oral anticoagulants
journal contribution
posted on 2023-05-21, 07:26 authored by Woldesellassie BezabheWoldesellassie Bezabhe, Luke BereznickiLuke Bereznicki, Janette RadfordJanette Radford, Barbara Wimmer, Mohammed SalahudeenMohammed Salahudeen, Ivan BindoffIvan Bindoff, Gregory PetersonGregory PetersonCompared with warfarin, prescribing of direct-acting oral anticoagulants (DOACs) was associated with a lower risk of renal function decline per 1000 person-years: hazard ratio (HR) 0.75, 95% confidence interval (CI) 0.68-0.81, p < 0.001 for ≥30% decline in eGFR; HR 0.28, 95% CI 0.20-0.41, p < 0.001 for eGFR decline to ≤30 mL/min/1.73 m2; and HR 0.45, 95% CI 0.35-0.58, p < 0.001 for serum creatinine doubling. Compared with dabigatran, rivaroxaban use had a significantly lowered risk of decline in eGFR to ≤30 mL/min/1.73 m2 (HR 0.29, 95% CI 0.13-0.66, p = 0.003) and risk of doubling of serum creatinine (HR 0.62, 95% CI 0.40-0.95, p = 0.030).
History
Publication title
Expert Review of Clinical PharmacologyVolume
15Pagination
359-364ISSN
1751-2433Department/School
School of Pharmacy and PharmacologyPublisher
Taylor & FrancisPlace of publication
United KingdomRights statement
Copyright 2022 Informa UK Limited, trading as Taylor & Francis GroupRepository Status
- Restricted